On August 4, Bruker fell 18.63% in regular trading, trading at $53.19/share, with turnover of $123 million. The decline was triggered by the company's Q2 earnings report, which showed a revenue miss and a downward revision to full-year revenue guidance.

Bruker reported Q2 adjusted earnings of $0.49 per diluted share, beating the analyst consensus estimate of $0.38-$0.39 by approximately 25%, representing a 53% increase from $0.32 a year ago. However, Q2 revenue came in at $838.5 million, below the analyst estimate of $853.6 million, despite rising from $797.4 million year-over-year.

More critically, the company cut its fiscal full-year revenue outlook to approximately $3.54 billion to $3.57 billion, down from the prior range of $3.57 billion to $3.60 billion, falling short of the analyst consensus of $3.59 billion. Full-year adjusted EPS guidance was maintained at $2.10 to $2.15 per share. Despite strong profitability, the revenue shortfall combined with the lowered outlook reflects slowing end-market demand growth, raising concerns over the company's forward momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)